Completed PHASE3 INTERVENTIONAL 3-arm NCT00853099

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Ulcerative Colitis

Interventions adalimumab placebo

Updated 6 times since 2017 Last updated: Sep 3, 2014 Started: Feb 28, 2009 Primary completion: May 31, 2011 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ulcerative Colitis, this trial is completed. The trial is conducted by AbbVie (prior sponsor, Abbott) and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asahikawa, Japan , Chiba, Japan , Chikushino-shi, Japan , Fukuoka, Japan , Hamamatsu, Japan , Hirakata-shi, Japan , Hirosaki, Japan , Hiroshima, Japan , Izumo, Japan , Kagoshima, Japan and 35 more locations